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Upper gastrointestinal (GI) cancers of the stomach and esophagus have high incidence and mortality
worldwide, but they are uncommon in Western countries. Little information exists on the association
between vitamin D and risk of upper GI cancers. This study examined the association between circulating
25-hydroxyvitamin D (25(OH)D) and upper GI cancer risk in the Cohort Consortium Vitamin D Pooling Project
of Rarer Cancers. Concentrations of 25(OH)D were measured from 1,065 upper GI cancer cases and 1,066
age-, sex-, race-, and season-of blood draw–matched controls from 8 prospective cohort studies. In multivariate-
adjusted models, circulating 25(OH)D concentration was not signiﬁcantly associated with upper GI cancer
risk. Subgroup analysis by race showed that among Asians, but not Caucasians, lower concentrations of
25(OH)D (<25 nmol/L) were associated with a statistically signiﬁcant decreased risk of upper GI cancer (reference:
50–<75 nmol/L) (odds ratio ¼ 0.53, 95% conﬁdence interval: 0.31, 0.91; P trend ¼ 0.003). Never smokers with
concentrations of <25 nmol/L showed a lower risk of upper GI cancers (odds ratio ¼ 0.55, 95% conﬁdence interval:
0.31, 0.96). Subgroup analyses by alcohol consumption produced opposing trends. Results do not support the
hypothesis that interventions aimed at increasing vitamin D status would lead to a lower risk of these highly fatal
cancers.
case-control studies; cohort studies; esophageal neoplasms; prospective studies; stomach neoplasms; vitamin D
Abbreviations: CI, conﬁdence interval; ESCC, esophageal squamous cell carcinoma; GI, gastrointestinal; 25(OH)D,
25-hydroxyvitamin D; OR, odds ratio; VDPP, Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
Upper gastrointestinal (GI) cancers of the stomach and
esophagus have high incidence and mortality worldwide,
but they are uncommon in Western countries. Few epidemi-
ologic studies have examined the association between vita-
min D and risk of upper GI cancers of the esophagus or
stomach. The major source of vitamin D for most people
is generation through the skin during exposure to ultraviolet
B radiation, whereas diet contributes little, especially
among those who do not consume vitamin D–fortiﬁed prod-
ucts or oily ﬁsh. Vitamin D can be antiproliferative in cells
of the skin, colon, breast, and prostate, among others, and
may also limit proinﬂammatory stresses (1).
Ecologic studies in the United States (2) and elsewhere
(3) have suggested an inverse correlation between estimated
ultraviolet exposure and upper GI cancer rates. However,
ecologic studies are principally hypothesis generating and
provide the weakest evidence because of the lack of indi-
vidual data on exposure and disease. In contrast, another
study reported a higher risk of second primary cancers in
internal organs, including the esophagus and stomach, after
94 Am J Epidemiol 2010;172:94–106a ﬁrst diagnosis of nonmelanoma skin cancer, but these
associations seemed limited to countries with lower ultravi-
olet exposure and did not show speciﬁcity by cancer site (4).
Another study built an index from factors that predict higher
serum 25-hydroxyvitamin D (25(OH)D) concentrations
(dietary and supplemental vitamin D, skin pigmentation,
adiposity, geographic region of residence, and leisure-
time physical activity) and found that index values that
predict higher vitamin D status were associated with a sta-
tistically signiﬁcant lower risk of esophageal cancer and a
non-statistically-signiﬁcant lower risk of stomach cancer
(5). This index, however, included exposures that may affect
cancer risk independent from their association with vitamin
D status.
Observational studies with individual exposure metrics
have produced mixed results. Case-control studies of upper
GI cancer examining dietary and/or supplemental vitamin D
have reported that higher vitamin D intake is associated with
lower risk of esophageal squamous cell carcinoma (ESCC)
(6), is associated with increased risk of gastric cancer (7), or
had no association with gastric cancer (8). A prospective
cohort study from China showed that higher serum
25(OH)D concentrations were associated with higher risk
of ESCC but had no association with risk of gastric cancer
(9). Another study in the same population showed that
higher 25(OH)D concentrations were associated with
higher risk of squamous dysplasia, the precursor lesion for
ESCC (10).
The current study examined the association between cir-
culating 25(OH)D concentration and upper GI cancer risk in
a nested case-control study combining gastric and esopha-
geal cancer cases and matched controls from 8 prospective
cohort studies from China, Finland, and the United States as
part of the Cohort Consortium Vitamin D Pooling Project of
Rarer Cancers (VDPP). To maximize power, total upper GI
cancer was the primary outcome.
MATERIALS AND METHODS
Study design and population
A detailed description of the cohorts and methods used in
the VDPP is provided in the paper by Gallicchio et al. (11).
The upper GI cancer analyses included esophageal and gas-
tric cancer cases from the following 8 cohorts: the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study
(ATBC); CLUE; the Cancer Prevention Study II (CPS-II)
Nutrition Cohort; the Multiethnic Cohort Study (MEC); the
New York University Women’s Health Study (NYU-WHS);
the Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial (PLCO); the Shanghai Men’s Health Study (SMHS);
and the Shanghai Women’s Health Study (SWHS). The num-
ber of subjects and other information for each cohort are
given in Table 1.
Tumor location and histologic coding methods varied by
study and included the International Classiﬁcation of Dis-
eases, Ninth Revision; International Statistical Classiﬁca-
tion of Diseases and Related Health Problems, Tenth
Revision; and country-speciﬁc methods. For the Interna-
tional Statistical Classiﬁcation of Diseases and Related
Health Problems, Tenth Revision, cases with epithelial tu-
mors located in the esophagus (codes C152–159), gastric
cardia (code C160), body of the stomach (codes C161–
166), and overlapping and not otherwise speciﬁed locations
(codes C168–169) were included. Cases were matched to
controls who were alive and cancer free at the time of case
diagnosis. Controls were matched within cohorts to cases on
age at blood collection (61year), sex,race/ethnicity (Asian/
black/Caucasian/other), and calendar day of blood draw
(630 days).
Of the 1,077 cases initially identiﬁed, 12 were excluded
because of a diagnostic date before blood draw (n ¼ 2),
ineligible histology (n ¼ 5), failed 25(OH)D assay (n ¼ 1),
Table 1. Characteristics of Participants, by Cohort, in the Investigation of Upper
Gastrointestinal Cancer Within the Cohort Consortium Vitamin D Pooling Project of Rarer
Cancers
Cohort No. of
Cases
No. of
Controls
Median Years From
Blood Collection to
Cancer Diagnosis
(Interquartile Range)
Median Circulating 25(OH)D, nmol/L
(Interquartile Range)
Cases Controls
ATBC 416 417 8.7 (5.1–13.1) 30.8 (20.0–43.3) 31.5 (19.6–46.8)
CLUE 88 88 10.6 (5.5–16.5) 59.3 (45.4–81.7) 61.5 (45.4–80.9)
CPS-II 40 40 1.9 (1.4–3.8) 58.4 (46.6–71.4) 58.2 (46.6–69.0)
MEC 82 82 2.2 (1.1–3.4) 47.8 (33.6–66.3) 47.0 (34.5–64.8)
NYU-WHS 27 27 11.8 (7.0–16.2) 41.0 (26.3–51.3) 38.6 (28.7–51.3)
PLCO 99 99 5.5 (2.9–6.9) 56.7 (42.4–68.3) 55.8 (41.1–68.5)
SMHS 131 131 1.7 (0.9–2.9) 41.8 (29.6–57.5) 39.0 (29.5–53.6)
SWHS 182 182 4.6 (2.5–6.6) 36.6 (24.3–47.5) 35.1 (24.7–45.7)
Total 1,065 1,066 5.3 (2.4–9.1) 39.4 (26.3–56.1) 39.3 (26.1–56.3)
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II,
Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NYU-WHS, New
York University Women’s Health Study; 25(OH)D, 25-hydroxyvitamin D; PLCO, Prostate, Lung,
Colorectal and Ovarian Cancer Screening Trial; SMHS, Shanghai Men’s Health Study; SWHS,
Shanghai Women’s Health Study.
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and 1,066 controls for analysis. Case and control numbers
are uneven because 1 subject was simultaneously diag-
nosed with esophageal and stomach cancer and was
matched to 2 different controls. In disease-stratiﬁed analy-
ses, this subject was included for both cancer sites but only
once in the total upper GI cancer analyses. Any upper
GI cancer was the main outcome to maximize power, but
subgroup analyses were conducted based on organ and his-
tology, where possible, including all esophageal cancer
(n ¼ 265), ESCC (n ¼ 142), esophageal adenocarcinoma
(n ¼ 104), all gastric cancers (n ¼ 784), gastric cardia
adenocarcinoma (n ¼ 135), and gastric noncardia adeno-
carcinoma (n ¼ 428).
Measurement of circulating 25(OH)D
Circulating (serum or plasma) 25(OH)D concentrations
were assayed by using a direct, competitive chemilumines-
cence immunoassay using the DiaSorin LIAISON 25 OH
Vitamin D TOTAL Assay (11, 12). Coefﬁcients of variation
for duplicate serum/plasma aliquots includedinall laboratory
sample batches were calculated by using the 2 masked stan-
dards provided by the National Institute of Standards and
Technology (NIST): level 1 (~60 nmol/L) and level 2
(~35 nmol/L). Interbatch and intrabatch coefﬁcients of vari-
ation for level 1 samples were 12.7% and 9.3%, respectively;
interbatch and intrabatch coefﬁcients of variation for level 2
samples were 13.6% and 11.0%, respectively. For all primary
analyses, a priori categories were used based on clinically
deﬁned cutpoints: <25, 25–<37.5, 37.5–<50, 50–<75,
75–<100, and  100 nmol/L. The category 50–<75 nmol/L
was chosenasthe reference because it encompassesthe mean
forsubjectsinthe NationalHealthandNutritionExamination
Survey (13). For some subgroup analyses, alternative con-
structs were used, including considering the <25 nmol/L
category as the referent group (to aid interpretability) and
using log-transformed continuous 25(OH)D (to potentially
maximize power and simplify presentation).
Statistical analyses
All statistical analyses were carried out at Information
Management Services, Inc. (Silver Spring, Maryland) by
Table 2. Selected Characteristics of Cases and Controls in the Investigation of Upper Gastrointestinal Cancer
Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Characteristic
Cases (N 5 1,065) Controls (N 5 1,066)
P Value
a
No. %
Median
(Interquartile
Range)
No. %
Median
(Interquartile
Range)
Age at blood draw, years 61 (55–67) 61 (55–66) Matched
Sex
Female 290 27 290 27 Matched
Male 775 73 776 73
Race/ethnic group
Caucasian 647 61 649 61 Matched
Black 30 3 30 3
Asian 350 33 349 33
Other 35 3 36 3
Missing 3 <12 <1
Cigarette smoking
Never 305 29 344 32 0.0001
Quit >15 years ago 85 8 107 10
Quit 10–15 years ago 62 6 40 4
Quit 1–<10 years ago 39 4 28 3
Current, <20 cigarettes/
day
214 20 250 23
Current,  20 cigarettes/
day
352 33 291 27
Missing 8 <16 <1
Alcohol intake, g/day
None 406 38 426 40 0.13
>0–14 284 27 316 30
>14–28 120 11 120 11
>28 153 14 122 11
Missing 102 10 82 8
Table continues
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Inc., Cary, North Carolina), and meta analyses were con-
ducted by using the R function MiMa (14). Reported P
values were derived from 2-sided tests, and those <0.05
were considered statistically signiﬁcant.
Conditional logistic regression models were used for the
primary analyses of the association between circulating
25(OH)D and upper GI cancer risk, whereas unconditional
models were used for stratiﬁed models. Estimated odds ra-
tios and 95% conﬁdence intervals were calculated by using
the 6 clinically deﬁned categories in models without further
adjustment and in multivariate-adjusted models. Trend tests
of the overall association were conducted by using a 1
degree-of-freedom test with subjects assigned a value of
1–6 based on their 25(OH)D category. Conditional and
unconditional models (data not shown) produced similar
results. Models using cohort- and season-speciﬁc quartiles
produced results similar to those using the clinically deﬁned
cutpoints (data not shown).
Potential confounding variables assessed included ciga-
rette smoking, alcohol drinking, educational attainment (as
a proxy for socioeconomic status), body mass index, and
history of gastric surgery where available. Bivariate analy-
ses to test for independent associations between potentially
confounding variables and both case status (conditional lo-
gistic regression) and circulating 25(OH)D concentrations
among controls (linear regression) based on the Wald test
were conducted. Variables with an independent association
with both case status and circulating 25(OH)D concentra-
tion (P < 0.10), as well as those with known associations
with cancer risk from previous studies, were retained; then,
a parsimonious ﬁnal model was built with a forward selec-
tion and backward elimination procedure, looking for
changes in the 25(OH)D betas of 610%. Body mass index
was excluded as a confounder and therefore the multivariate
models included cigarette smoking, alcohol drinking, edu-
cation, and history of gastric surgery as categorized in
Table 2. For variables for which data were missing,
Table 2. Continued
Characteristic
Cases (N 5 1,065) Controls (N 5 1,066)
P Value
a
No. %
Median
(Interquartile
Range)
No. %
Median
(Interquartile
Range)
Education
Less than high school 440 41 384 36 0.0062
Completed high school 157 15 164 15
Vocational school 211 10 202 19
Some college 160 15 186 18
College graduate 47 4 71 7
Graduate studies 40 4 51 5
Missing 10 1 8 1
Body mass index, kg/m
2 25.3 (22.9–28.2) 25.3 (23.1–28.1) 0.51
History of gastric surgery
No 620 58 758 71 0.0003
Yes 41 4 16 2
Missing 404 38 292 27
Season of blood draw
Winter 560 53 556 52 0.55
Summer 505 47 510 48
Serum 25(OH)D
concentration,
nmol/L
39.4 (26.3–56.1) 39.1 (25.8–56.7) 0.90
Serum 25(OH)D
concentration
category, nmol/L
<25 241 22.7 252 23.6 0.97
25–<37.5 248 23.2 239 22.4
37.5–<50 224 21.0 223 20.9
50–<75 249 23.4 252 23.6
75–<100 83 7.8 77 7.2
 100 20 1.9 23 2.2
Abbreviation: 25(OH)D, 25-hydroxyvitamin D.
a Wald test from conditional logistic regression, excluding subjects with missing data.
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cases and 27% of controls), ethnicity, smoking, alcohol
drinking,andeducation(missingfor 1%ofsubjects),acat-
egorical variable to account for missingness was included.
Unconditional models included both the matching and ad-
ditional adjustment variables.
Stratiﬁed analyses were conducted by season (summer
(June–November)/winter (December–May)), sex, organ, or-
gan and histology,smoking (never/ever),alcohol drinking (4
categories), and length of follow-up (<2 years,  2 years).
Models stratiﬁed on alcohol drinking did not include some
adjusting variables because of small cell counts. We found
no differences by follow-up time (data not shown). Stratiﬁed
analysis by age, body mass index, physical activity, and
follow-up time were conducted by using long-transformed
continuous concentrations. Seasonally adjusted 25(OH)D
concentrations were created by using the residuals after re-
gression against week of blood draw using the local poly-
nomial regression (loess) method. These results were
similar to the non-seasonally-adjusted results and are not
shown in this paper.
In addition to the pooled analysis described above,
a meta-analysis approach was also used (14). For each
cohort separately, with 50–<75 nmol/L as the referent
category, odds ratios and 95% conﬁdence intervals for
subjects in the bottom (<25 nmol/L) category and for the
top 2 categories combined ( 75 nmol/L) were estimated.
Pooled estimates of effect using inverse-variance-weighted
random-effects models were calculated and statistical
heterogeneity assessed by Q and I
2 statistics.
RESULTS
Table 1 presents the number of cases and controls from
each cohort, the median time from blood draw to case di-
agnosis, and the median (interquartile range) circulating
25(OH)D concentration by cohort. Median follow-up time
ranged from 1.7 years in the Shanghai Men’s Health Study
to 11.8 years in the New York University Women’s Health
Study. The Alpha-Tocopherol, Beta-Carotene Cancer Pre-
vention Study had the lowest median 25(OH)D concentra-
tion at 31.5 nmol/L among controls, whereas CLUE had the
highest at 61.5 nmol/L. Median concentrations by cohort
varied based on the sex ratios, ethnic makeup, seasons of
blood collection, and other factors. The predictors of
25(OH)D concentration inthe VDPP cohortswere evaluated
separately (15).
Table 2 shows subject characteristics by case status. Com-
pared with controls, upper GI cancer cases reported signif-
icantly more cigarette smoking and less education, and they
were more likely to report a history of gastric surgery. Cases
and controls did not differ in body mass index and were
comparable regarding matching factors.
Median circulating 25(OH)D concentration did not differ
signiﬁcantly (P ¼ 0.90) between upper GI cancer cases and
controls—39.4 nmol/L (interquartile range: 26.3–56.1) and
39.1 nmol/L (interquartile range: 25.8–56.7), respectively
(Table 2). Furthermore, the distribution of cases and con-
trols did not differ across the 6 categories of 25(OH)D
(P ¼ 0.97).
Table 3 presents the results of primary analyses of the
association between circulating 25(OH)D concentration
and risk of upper GI cancer overall, by season and by sex.
Multivariate adjustment for potentially confounding factors
had little impact on the estimates. In the overall analysis and
in all subgroupings presented here, no association between
25(OH)D concentration and risk of upper GI cancer was
observed. No stratum showed statistically signiﬁcant asso-
ciations for individual categories or trend tests. Further sub-
dividing into 4 strata according to sex and season also
showed no signiﬁcant associations (data not shown).
Subgroup analyses by organ site and histology are shown
in Table 4. No associations were observed for total esopha-
geal cancer or when subdivided into the 2 histologic types
ESCC and esophageal adenocarcinoma. Total gastric cancer
showed no association, but when divided into the 2 primary
gastric subsites, cardia and noncardia stomach, an increased
risk of gastric noncardia cancer with higher circulating
25(OH)D concentration was observed. Compared with the
reference group (50–<75 nmol/L), those in the higher cat-
egory (75–<100 nmol/L) were at statistically signiﬁcantly
higher risk (odds ratio (OR) ¼ 2.00, 95% conﬁdence inter-
val (CI): 1.03, 3.91. The test for trend across categories was
P ¼ 0.083.
Among never smokers, those in the lowest category of
25(OH)D concentrations were at lower risk of upper GI
cancer compared with the reference group (OR ¼ 0.55,
95% CI: 0.31, 0.96), with a statistically signiﬁcant test for
trend (P ¼ 0.004). No statistically signiﬁcant associations
were observed among ever smokers (Table 4).
In models stratiﬁed on alcohol drinking, some differences
were found (Table 4). Subjects consuming more than 14 g
of alcohol a day showed higher risk of upper GI cancer at
lower vitamin D concentrations, whereas an opposite trend
appeared to be present among those who did not drink
alcohol.
Associations varied by race (Table 5), but sufﬁcient num-
bers to examine models separately were available for only
Asians and Caucasians. Among Asians, a statistically sig-
niﬁcant decreased risk of upper GI cancer was observed
with lower concentrations, with a signiﬁcant trend across
categories of 25(OH)D concentration (P ¼ 0.003). For ex-
ample, subjects in the lowest category (<25 nmol/L) had
a 47% (95% CI: 9, 69) lower risk of upper GI cancer than
those in the referent group (50–<75 nmol/L). To simplify
interpretation, models were also ﬁt by using the lowest cat-
egory as the referent. The odds ratio estimates for increas-
ing 25(OH)D categories were 1.0 (reference), 0.94 (95% CI:
0.60, 1.48), 0.96 (95% CI: 0.59, 1.56), 1.88 (95% CI: 1.10,
3.22), 3.56 (95% CI: 1.39, 9.14), and 1.85 (95% CI: 0.44,
7.75). Although sample sizes became sparse, further strat-
iﬁcation by season or by sex found signiﬁcant trend tests in
all subgroups of Asians except women alone. Among Cau-
casians, no statistically signiﬁcant associations were ob-
served between circulating 25(OH)D and risk of upper GI
cancer overall or in groups deﬁned by sex or season. Strat-
iﬁed analyses among the overall population by age, body
mass index, physical activity, and follow-up time showed
no evidence that the associations differed by these strata
(Table 6).
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Am J Epidemiol 2010;172:94–106Table 3. Odds Ratios and 95% Conﬁdence Intervals for the Association Between Circulating 25(OH)D and Risk of Upper Gastrointestinal Cancer Overall and by Season or Sex Within the
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Circulating 25(OH)D, nmol/L Ptrend
<25 25–<37.5 37.5–<50 50–<75
a 75–<100 ‡100
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
All subjects
b 241 252 248 239 224 223 249 252 83 77 20 23
Crude 0.96 0.72, 1.28 1.04 0.80, 1.37 1.02 0.79, 1.33 1.0 1.09 0.76, 1.57 0.88 0.45, 1.70 0.79
Multivariate
adjusted
0.90 0.65, 1.24 1.03 0.76, 1.39 0.92 0.69, 1.23 1.0 1.17 0.79, 1.75 0.81 0.39, 1.69 0.54
All subjects,
winter
c
183 202 161 136 105 110 83 80 24 25 4 3
Crude 0.89 0.60, 1.32 1.16 0.78, 1.74 0.93 0.62, 1.42 1.0 0.96 0.50, 1.84 1.20 0.24, 5.94 0.71
Multivariate
adjusted
0.87 0.57, 1.31 1.13 0.74, 1.72 0.89 0.58, 1.38 1.0 0.82 0.41, 1.65 0.97 0.17, 5.43 0.81
All subjects,
summer
c
58 50 87 103 119 113 166 172 59 52 16 20
Crude 1.18 0.75, 1.87 0.86 0.60, 1.25 1.07 0.76, 1.51 1.0 1.17 0.76, 1.81 0.83 0.41, 1.69 1.00
Multivariate
adjusted
0.90 0.55, 1.46 0.79 0.53, 1.17 0.98 0.68, 1.40 1.0 1.30 0.82, 2.06 0.83 0.40, 1.74 0.23
Men
b 177 190 176 152 149 155 190 193 63 65 20 21
Crude 0.95 0.68, 1.33 1.19 0.86, 1.63 0.99 0.72, 1.34 1.0 0.97 0.64, 1.47 0.95 0.48, 1.89 0.85
Multivariate
adjusted
0.89 0.61, 1.31 1.23 0.85, 1.76 0.87 0.62, 1.24 1.0 1.03 0.65, 1.64 0.88 0.41, 1.89 0.97
Women
b 64 62 72 87 75 68 59 59 20 12 0 2
Crude 0.98 0.55, 1.73 0.79 0.46, 1.34 1.10 0.66, 1.83 1.0 1.83 0.81, 4.14 0.39
Multivariate
adjusted
0.88 0.47, 1.65 0.78 0.44, 1.38 0.96 0.56, 1.67 1.0 1.79 0.74, 4.33 0.34
Abbreviations: CI, conﬁdence interval; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a Reference category.
b Conditional logistic regression models were matched on cohort, race, sex, and date of blood draw without or with further adjustment for alcohol drinking, smoking, education, and history of gastric surgery.
c Unconditional logistic regression models were adjusted for the matching factors cohort, race, sex, and date of blood draw without or with further adjustment for alcohol drinking, smoking, education, and history of gastric surgery.
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6Table 4. Odds Ratios and 95% Conﬁdence Intervals
a for the Association Between Circulating 25(OH)D and Risk of Upper Gastrointestinal Cancer by Organ, Organ Subsite, Histology, and
Smoking Status Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Circulating 25(OH)D, nmol/L
Ptrend
<25 25–<37.5 37.5–<50 50–<75
b 75–<100 ‡100
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
Esophageal, all 54 44 42 51 56 53 76 79 26 28 11 9
Multivariate
adjusted
1.07 0.55, 2.10 0.70 0.38, 1.30 1.04 0.60, 1.80 1.0 0.98 0.48, 1.98 1.06 0.37, 3.05 0.80
Esophageal,
ESCC
44 32 24 37 33 29 32 33 7 8 2 3
Multivariate
adjusted
1.38 0.53, 3.57 0.49 0.20, 1.22 1.16 0.50, 2.66 1.0 0.96 0.23, 3.92 0.68 0.076, 6.02 0.77
Esophageal, EADC 8 10 15 11 19 20 36 38 17 18 9 6
Multivariate
adjusted
0.61 0.47, 3.96 1.36 0.47, 3.96 0.95 0.39, 2.28 1.0 1.10 0.43, 2.83 1.17 0.30, 4.45 0.70
Gastric, all 183 202 201 187 164 167 171 165 56 49 9 14
Multivariate
adjusted
0.77 0.55, 1.08 0.99 0.71, 1.36 0.88 0.64, 1.22 1.0 1.11 0.70, 1.77 0.65 0.26, 1.62 0.25
Gastric, cardia 34 40 29 33 29 23 32 25 9 9 2 5
Multivariate
adjusted
0.64 0.26, 1.62 0.70 0.29, 1.71 1.12 0.46, 2.71 1.0 0.65 0.18, 2.32 0.12 0.011, 1.25 0.88
Gastric, noncardia 103 115 115 116 99 96 86 87 35 19 1 6
Multivariate
adjusted
0.74 0.47, 1.17 0.87 0.56, 1.35 0.91 0.59, 1.41 1.0 2.00 1.03, 3.91 0.10 0.01, 0.99 0.083
Never smoker
c 51 58 65 89 69 88 86 79 27 25 7 5
Multivariate
adjusted
0.55 0.31, 0.96 0.47 0.28, 0.78 0.56 0.35, 0.90 1.0 1.24 0.63, 2.44 1.47 0.41, 5.30 0.004
Ever smoker
c 189 194 183 147 151 134 162 171 54 52 13 18
Multivariate
adjusted
1.02 0.72, 1.45 1.38 0.98, 1.95 1.20 0.85, 1.69 1.0 1.07 0.67, 1.69 0.68 0.30, 1.49 0.49
Nondrinker
d 93 107 98 117 85 98 98 82 25 16 5 5
Multivariate
adjusted
0.75 0.48, 1.16 0.70 0.46, 1.07 0.72 0.47, 1.09 1.0 1.32 0.66, 2.66 0.88 0.24, 3.16 0.081
Drinks >0–14 g/day
of alcohol
c 66 75 57 65 55 59 68 78 33 30 5 8
Multivariate
adjusted
0.94 0.57, 1.53 0.95 0.57, 1.57 1.02 0.62, 1.68 1.0 1.19 0.65, 2.17 0.72 0.22, 2.34 0.64
Drinks >14 g/day
of alcohol
d 65 57 76 45 60 51 53 64 14 14 5 8
Multivariate
adjusted
1.42 0.83, 2.45 2.06 1.20, 3.54 1.39 0.81, 2.38 1.0 0.96 0.43, 2.14 0.69 0.21, 2.27 0.034
Missing data for
alcohol
drinking
d
17 13 17 12 23 14 29 27 10 14 5 2
Multivariate
adjusted
1.30 0.48, 3.56 1.36 0.49, 3.79 1.54 0.64, 3.70 1.0 0.65 0.24, 1.74 2.37 0.42, 13.37 0.55
Abbreviations: CI, conﬁdence interval; EADC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a Unconditional logistic regression models were adjusted for the matching factors cohort, race, sex, and date of blood draw, with further adjustment for alcohol drinking, smoking, education, and history of gastric surgery. The adjustments for
models stratiﬁed on alcohol drinking are given in footnote c.
b Reference category.
c The test for interaction with smoking was statistically signiﬁcant, P ¼ 0.015.
d Unconditional logistic regression models were adjusted for the matching factors race, sex, and date of blood draw, without further adjustment. The test for interaction with drinking was statistically signiﬁcant, P ¼ 0.0025.
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6Table 5. Odds Ratios and 95% Conﬁdence Intervals
a for the Association Between Circulating 25(OH)D and Risk of Upper Gastrointestinal Cancer by Ethnic Group, by Season and Sex
Within Ethnic Group, Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
Circulating 25(OH)D, nmol/L
Ptrend
<25 25–<37.5 37.5–<50 50–<75
b 75–<100 ‡100
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR
No.
of
Cases
No.
of
Controls
OR 95%
CI
No.
of
Cases
No.
of
Controls
OR 95%
CI
Asians, all 67 71 92 111 73 88 88 63 24 11 6 5
Multivariate
adjusted
0.53 0.31, 0.91 0.50 0.31, 0.80 0.51 0.32, 0.82 1.0 1.89 0.78, 4.60 0.99 0.25, 3.91 0.003
Asians, winter 52 55 60 63 31 37 25 12 7 5 1 0
Multivariate
adjusted
0.29 0.11, 0.73 0.29 0.12, 0.72 0.27 0.10, 0.69 1.0 0.76 0.13, 4.30 0.049
Asians, summer 15 16 32 48 42 51 63 51 17 6 5 5
Multivariate
adjusted
0.79 0.34, 1.83 0.57 0.31, 1.05 0.67 0.37, 1.21 1.0 3.24 1.03, 10.17 1.06 0.23, 4.91 0.027
Asians, men 19 24 41 45 26 42 51 37 18 9 6 4
Multivariate
adjusted
0.46 0.20, 1.08 0.57 0.29, 1.12 0.38 0.19, 0.78 1.0 2.05 0.70, 6.01 1.28 0.28, 5.91 0.014
Asians, women 48 47 51 66 47 46 37 26 6 2 0 1
Multivariate
adjusted
0.65 0.31, 1.34 0.51 0.26, 1.01 0.68 0.34, 1.33 1.0 2.01 0.35, 11.48 0.16
Caucasians, all 155 167 140 115 134 115 150 172 54 62 14 18
Multivariate
adjusted
0.98 0.67, 1.44 1.43 0.98, 2.08 1.28 0.89, 1.84 1.0 1.07 0.68, 1.69 0.81 0.37, 1.79 0.69
Caucasians,
winter
119 140 93 67 71 65 51 58 16 16 3 3
Multivariate
adjusted
0.98 0.58, 1.65 1.73 1.00, 2.97 1.25 0.72, 2.17 1.0 1.00 0.41, 2.40 0.77 0.11, 5.28 0.98
Caucasians,
summer
36 27 47 48 63 50 99 114 38 46 11 15
Multivariate
adjusted
1.06 0.54, 2.10 1.09 0.63, 1.90 1.37 0.83, 2.27 1.0 1.07 0.62, 1.85 0.78 0.32, 1.91 0.57
Caucasians,
men
149 159 127 102 114 101 132 146 42 54 14 17
Multivariate
adjusted
0.94 0.63, 1.40 1.40 0.93, 2.10 1.20 0.81, 1.77 1.0 0.91 0.55, 1.51 0.85 0.37, 1.90 0.73
Caucasians,
women
6 8 13 13 20 14 18 26 12 8 0 1
Multivariate
adjusted
0.80 0.17, 3.71 1.71 0.50, 5.92 1.42 0.46, 4.38 1.0 2.95 0.76, 11.46 0.73
Abbreviations: CI, conﬁdence interval; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.
a Unconditional logistic regression models were adjustedfor the matching factors cohort, race,sex, anddate of blood draw, with further adjustment for alcohol drinking, smoking,education, andhistory ofgastric surgery, as appropriate within
strata. The test for interaction with ethnicity was statistically signiﬁcant, P ¼ 0.0021.
b Reference category.
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6Models for each of the 4 speciﬁc cancer outcomes that
were simultaneously stratiﬁed on ethnicity, smoking, or
alcohol drinking had small numbers and produced most risk
estimates with wide conﬁdence intervals (data not shown).
These results were similar to those presented in that low
vitamin D concentrations were associated with lower risk
of noncardia gastric cancer in Asians and lower risk of
esophageal adenocarcinoma in whites. In contrast, risk of
ESCC was nonsigniﬁcantly higher with lower concentra-
tions in whites and Asians.
Finally, the association between circulating 25(OH)D
concentration and upper GI cancer risk was examined by
using a meta-analysis framework. Figure 1 shows the odds
ratio in each cohort separately comparing those in the <25
nmol/L group with the referent group of 50–<75 nmol/L
and those in the  75 nmol/L group compared with the
same group. For subjects with circulating concentrations
of <25 nmol/L, most estimates were below unity, and the
summary odds ratio across cohorts was 0.89 (95% CI: 0.47,
1.66), although there was some heterogeneity in these esti-
mates (I
2 ¼ 39%; P ¼ 0.14). The estimate for the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study cohort
appeared to differ from the rest in showing signiﬁcantly
increased risk (OR ¼ 1.85, 95% CI: 1.06, 3.21). For subjects
with circulating concentrations of  75 nmol/L, risk esti-
mates centered on unity with an odds ratio across cohorts
of 1.06 (95% CI: 0.67, 1.68) and little heterogeneity (I
2 ¼
9%; P ¼ 0.36).
DISCUSSION
This study examined the association between circulating
25(OH)D concentrations and upper GI cancer risk in a
combined analysis nested in 8 prospective cohort studies.
Overall, no association between circulating 25(OH)D
concentration and risk of upper GI cancers was observed.
Surprisingly, in models stratiﬁed by race/ethnic group or
smoking, therewas evidence of a protectiveassociation with
lower vitamin D status and cancer risk. In models stratiﬁed
on alcohol drinking, 2 opposing trends were evident. For
subjects reporting no alcohol consumption, having a lower
concentration of circulating vitamin D was associated with
lower cancer risk; for those reporting consumption of more
than 14 g of alcohol a day, lower concentrations were asso-
ciated with higher risk of cancer. Among Asians, most of
whom participated in the 2 Shanghai cohorts of Han Chi-
nese, and among never smokers, the risk of cancer was
statistically signiﬁcantly lower for subjects with circulating
concentrations of <50 nmol/L compared with those with
higher concentrations. Speciﬁcally, compared with a circu-
lating 25(OH)D concentration of 50–75 nmol/L, a range that
encompasses the mean for subjects in the National Health
and Nutrition Examination Survey, the odds ratio for Asian
subjects with a circulating concentration of <25 nmol/L was
0.53 (95% CI: 0.31, 0.91).
Similarly, for never smokers, the same contrast produced
an odds ratio of 0.55 (95% CI: 0.31, 0.96). The estimate in
the Alpha-Tocopherol, Beta-Carotene Cancer Prevention
Study cohort, whose members were all active smokers, ap-
peared to differ from that in the other cohorts, showing that
subjects in the lowest 25(OH)D category had higher risk of
upper GI cancer (OR ¼ 1.85, 95% CI: 1.06, 3.21). This
ﬁnding is consistent with the possibility that smoking status
may modify the association of vitamin D with upper GI
cancer risk. All these stratiﬁed estimates should be inter-
preted with caution because these stratiﬁcations also altered
the primary outcomes examined (e.g., more ESCC among
the alcohol drinkers), and it altered the relative representa-
tion of different cohorts (e.g., all Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study subjects were among the
ever smokers). However, these subgroup analyses strongly
suggest that each disease subtype should be examined sep-
arately in large studies to clarify these potential interactions.
To our knowledge, only 2 previous studies have tested the
association between circulating vitamin D status and risk of
upper GI cancer, and both were conducted in China and
examined Han Chinese (9, 10). In a prospective study, a se-
rum 25(OH)D concentration of <20 nmol/L compared
with >48 nmol/L conveyed a signiﬁcantly reduced risk of
0.56 for ESCC in men but showed no association among
women. In contrast, there was no evidence of association
with risk of gastric cancer in either sex in that study. A
subsequent cross-sectional study in the same population
showed lower risk of esophageal squamous dysplasia, the
preneoplastic lesion for ESCC, with lower serum 25(OH)D
status. The results of the present study among Asian partic-
ipants, most of whom were Han Chinese, were similar re-
garding the direction of association. Our sample size among
Asians was too small to test for distinct associations by
Table 6. Odds Ratios and 95% Conﬁdence Intervals for the
Association Between Circulating 25(OH)D
a and Risk of Upper
Gastrointestinal Cancer by Selected Strata Within the Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers
OR 95% CI
Age at blood draw, years
 61 1.07 0.84, 1.36
>61 1.06 0.80, 1.39
Body mass index, kg/m
2
<25 1.00 0.77, 1.30
25–<30 1.28 0.94, 1.74
 30 0.82 0.47, 1.43
Physical activity
Sedentary 0.97 0.73, 1.30
Light 0.98 0.69, 1.38
Moderate 1.60 0.85, 3.00
Vigorous 1.10 0.63, 1.91
Follow-up time, years
<2 1.19 0.83, 1.71
 2 1.04 0.84, 1.28
Abbreviations:CI,conﬁdenceinterval;25(OH)D,25-hydroxyvitaminD;
OR, odds ratio.
a Modeled as 1 log unit of 25(OH)D in unconditional logistic regres-
sion models adjusted for the matching factors cohort, race, sex, and
date of blood draw, with further adjustment for alcohol drinking, smok-
ing, education, and history of gastric surgery, as appropriate within
strata.
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Cohort OR (95% CI) Cases  Controls
ATBC 1.85 (1.06, 3.21)   
CLUE 0.37 (0.05, 2.78)
CPS-II 0.62 (0.01, 45.7)
MEC 0.61 (0.17, 2.22)
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PLCO 0.77 (0.13, 4.67)
SMHS/SWHS 0.65 (0.35, 1.20)
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Figure 1. Forest plots for the meta-analysis of the association between circulating 25-hydroxyvitamin D (25(OH)D) and the risk of esophageal and gastric cancer within the Cohort Consortium
Vitamin D Pooling Project of Rarer Cancers. Risk estimates, by cohort, for subjects with circulating 25(OH)D concentrations of A) <25 nmol/L and B)  75 nmol/L compared with the referent group
(50–<75 nmol/L). Odds ratios (ORs) and 95% conﬁdence intervals (CIs) were derived from conditional logistic regression models. The boxes show the odds ratios, the bars show the 95%
conﬁdence intervals, and the size of each box is inversely proportional to the variance of the log odds ratio estimate in each cohort. The overall estimates (diamonds) were derived from a meta-
analysis using random-effects modeling. No estimates are given for the NYU-WHS because of small numbers in the exposed group. For the <25 nmol/L comparison, I
2 was 39%; for the  75
nmol/L comparison, I
2 was 9%. ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CPS-II, Cancer Prevention Study II Nutrition Cohort; GI, gastrointestinal; MEC, Multiethnic
Cohort Study; NYU-WHS, New York University Women’s Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SMHS/SWHS, Shanghai Men’s Health Study/
Shanghai Women’s Health Study.
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6cancer type, butthe adverse association was apparent in both
sexes, a ﬁnding that differs from the previous report (9).
Studies of other cancer sites in the VDPP have also ob-
served an association between higher vitamin D status and
increased cancer risk. As in a previous study of the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study cohort
alone (16), higher vitamin D status was associated with in-
creased risk of pancreatic cancer. Here, a 2-fold increase in
risk was seen for subjects with a 25(OH)D concentration
of >100 nmol/L (17). In addition, the analysis of non-
Hodgkin lymphoma suggested an association of increased
risk with higher vitamin D status in women (18).
As in all observational epidemiologic studies, the results
of this analysis should be interpreted with caution because
unmeasured or poorly measured confounders could obscure
the true association. Furthermore, the signiﬁcant differences
we observed were apparent only in subgroups. However, the
magnitude of the estimated risks in these subgroups and the
observed dose-response associations were such that any un-
measured factor would need to have a strong association
with upper GI cancer risk and also be well correlated with
vitamin D status to confound the associations observed.
One possible source of confounding not included in our
pooled analysis study was occupation. Some jobs that con-
vey lower socioeconomic status, which may increase the
risk of upper GI cancers, may also entail more sun expo-
sure. This potential confounding by occupation was ex-
plored in the Shanghai cohorts (data not shown), but
these analyses did not suggest that occupational differ-
ences would explain the adverse association among
Asians. Other potential confounders were considered in
the analyses. Among Asian controls in the VDPP, alcohol
consumption and vitamin D intake (primarily from ﬁsh)
was associated with higher circulating 25(OH)D, whereas
current smoking was associated with signiﬁcantly lower
circulating 25(OH)D (15). Because the models were ad-
justed for alcohol consumption and cigarette smoking,
and because smoking was correlated with lower 25(OH)D
concentration, confounding by smoking is unlikely to explain
the association among Asians.
Several biologic rationales have been postulated for pos-
sible adverse associations between higher vitamin D status
and increased cancer risk, including induction of phase I
metabolizing enzymes under certain conditions (19), which
may be relevant in some populations. Second, the vitamin D
pathway can have both proliferative and antiproliferative
effects on preneoplastic lesions in an organ-speciﬁc manner.
In cells molecularly similar to esophageal squamous dyspla-
sia in their ratio of E-cadherin to osteopontin, vitamin D
may stimulate cell proliferation; in cells molecularly similar
to colon polyps in their ratio of E-cadherin to osteopontin,
vitamin D appears to be antiproliferative (20). However,
these hypotheses remain speculative. Alternatively, vitamin
D status may change with occult cancer such that reverse
causation contributes to the apparent adverse association.
Future analyses of these cohorts are warranted because the
relatively short median follow-up in the Shanghai Men’s
Health Study, a major contributor of the Asian subjects in
the analysis, leaves open the possibility that occult cancers
inﬂuenced vitamin D concentrations.
This study has several strengths. The combination of mul-
tiple populations from diverse geographic locations pro-
vided a wide distribution of exposure to circulating
25(OH)D concentrations. Using 8 cohorts supplied a rela-
tively large sample size for these cancers in a prospective
study. Furthermore, all samples were measured by using the
same methods in a single facility. Weaknesses of the study
include combining cancers with some disparate risk factors
under a single outcome of upper GI cancer, although anal-
yses were also conducted by cancer type. In addition, data
on several potential confounding risk factors, including
Helicobacter pylori status for gastric cancer and history of
gastroesophageal reﬂux disease for esophageal adenocarci-
nomas, were not available. However, no data suggest that
these factors are related to vitamin D status and could con-
found results.
In this combined analysis of 8 prospective cohorts, no
overall association between circulating 25(OH)D concentra-
tion and risk of upper GI cancers was observed. In subgroup
analyses, an adverse association between higher vitamin D
status and upper GI cancer risk for Asians and for never
smokers, and opposing trends in subgroups deﬁned by alco-
hol consumption, suggested that the association may differ
by major risk factors for upper GI cancer or among individ-
uals with different risk-factor proﬁlesfor upper GI cancer.In
summary, these results do not support the hypothesis that
interventions aimed at increasing vitamin D status would
lead to lower risk of these highly fatal cancers.
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